BioXell announces change in management

09-Sep-2009 - BioXell S.p.A. announced the termination on the basis of a mutual agreement of the employment relationship with Bertrand Lehuu, Chief Business Officer. His responsibilities will be taken over by the company's Chief Executive Officer, Niels Ackermann. "I would like to thank Bertrand Lehuu for ...

BioXell S.p.A. announces change in management

29-Jul-2008 - BioXell S.p.A. announced that Enrico Colli, Chief Medical Officer, has resigned from the Company for personal reasons in order to pursue a career at a large pharmaceutical organization. He is expected to leave the Company at the end of September. Francesco Sinigaglia, Chief Executive Officer, ...

BioXell confirms strong potential of Elocalcitol

19-Oct-2007 - At its second annual R&D Day in Zurich, BioXell presented further analysis of its Phase IIb trial data in Benign Prostatic Hyperplasia (BPH), confirming that Elocalcitol has strong potential to become a new first-line monotherapy for BPH. Current BPH first-line therapies consist of combinations ...

BioXell announces positive Phase IIb results for Elocalcitol in Benign Prostatic Hyperplasia

Primary endpoint met - Elocalcitol highly effective in arresting prostate growth

15-Oct-2007 - BioXell S.p.A. announced top-line results of its Phase IIb trial of Elocalcitol in Benign Prostatic Hyperplasia (BPH). The primary endpoint was met with a high degree of statistical significance, with Elocalcitol effectively arresting prostate growth. Elocalcitol also showed relevant effects on ...

BioXell Announces New Members of Management Team

27-Mar-2007 - BioXell S.p.A. announced that Niels Ackermann will be joining the Company as Chief Financial Officer as of April 16, 2007, and that Bertrand Lehuu has joined the Company as Chief Business Officer since March 1, 2007. Alex Martin, who has held the positions of CBO and, currently, CFO, will be ...

BioXell acquires novel compound from Roche

BXL746 to enter Phase II trials for post-surgical adhesions

15-Jan-2007 - BioXell S.p.A. announced its decision to exercise the option rights it acquired from Roche for BXL746, a novel vitamin D3 analogue. Based on promising preclinical data, BXL746 will be moved into Phase II clinical development for the treatment of post-surgical adhesions. Financial terms of this ...

BioXell Appoints Thomas Szucs as New Chairman of the Board of Directors

02-Nov-2006 - BioXell S.p.A. announced that Thomas Szucs, member of its Board of Directors, has been appointed Chairman of the Board, replacing Michael Steinmetz who will remain on the Board. Joining BioXell's Board of Directors is Werner Lanthaler, CFO of Intercell. Both appointments are effective ...

BioXell Reports Preliminary Phase IIa Results in Non-Bacterial Chronic Prostatitis

Effect on pain comparable to placebo, effect observed on inflammation and lower urinary tract symptoms

29-Sep-2006 - BioXell S.p.A. reported preliminary results from its proof of concept trial of Elocalcitol in patients with Non-bacterial Chronic Prostatitis. The effect of Elocalcitol was found to be no different from that of placebo on the primary endpoint, focused mainly on pelvic pain. In contrast, positive ...

BioXell Plans Phase IIb European Trial for Elocalcitol in Overactive Bladder

31-Jul-2006 - BioXell S.p.A. announced its plans to proceed with a Phase IIb clinical trial of its lead compound Elocalcitol in Overactive Bladder (OAB). Enrolment in the pan-European study is scheduled to begin in early 2007. Details of the study design are currently being finalised. The new study follows ...

BioXell Raises Additional EUR10.5 million in Private Financing Led by TVM Capital

17-Mar-2006 - BioXelly announced that it has raised EUR10.5 million in financing through an extension of the Series C round concluded in October, 2004. International life science investor TVM Capital led the financing, while BB Biotech, Index Ventures and Life Science Partners also increased their position in ...